Table 8a.
Infants (12 weeks–11 months) | Toddlers (12–35 months) | Children (3–9 years) | Adolescents (10–17 years) | Adults (18–64 years) | The elderly (≥ 65 years) | |
---|---|---|---|---|---|---|
Regulatory maximum level exposure assessment scenario considering the extension of use in FC 05.2 only | ||||||
• Mean | 198–998 | 446–1,555 | 725–1,751 | 857–1,945 | 850–1,867 | 890–1,848 |
• 95th percentile | 419–1,714 | 754–2,052 | 1,070–2,959 | 1,461–3,462 | 1,530–3,638 | 1,510–3,551 |
Refined estimated exposure assessment scenario considering extension of use in FC 05.2 | ||||||
Brand‐loyal scenario | ||||||
• Mean | 96–309 | 101–372 | 108–620 | 130–733 | 319–722 | 337–747 |
• 95th percentile | 222–570 | 203–745 | 215–1,291 | 287–1,603 | 658–1,600 | 683–1,559 |
Non‐brand‐loyal scenario | ||||||
• Mean | 81–141 | 78–152 | 69–237 | 74–298 | 126–278 | 121–241 |
• 95th percentile | 191–253 | 153–266 | 135–613 | 155–749 | 253–636 | 212–480 |